Detalles de la búsqueda
1.
Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice.
Pharm Res
; 37(8): 164, 2020 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32901384
2.
Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft model.
Biopharm Drug Dispos
; 41(7): 283-294, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32562504
3.
The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats.
Drug Metab Dispos
; 47(9): 1004-1012, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31201213
4.
Investigation of disposition for TAK-448, a synthetic peptide of kisspeptin analog, in rats and dogs using the radiolabeled TAK-448 suitable for pharmacokinetic study.
Xenobiotica
; 49(7): 833-839, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30044673
5.
Mechanism for Covalent Binding of MLN3126, an Oral Chemokine C-C Motif Receptor 9 Antagonist, to Serum Albumins.
Drug Metab Dispos
; 46(3): 204-213, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29269409
6.
Long-Term Stability of Cryopreserved Human Hepatocytes: Evaluation of Phase I and II Drug-Metabolizing Enzyme Activities and CYP3A4/5 Induction for More than a Decade.
Drug Metab Dispos
; 45(7): 734-736, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28411281
7.
In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker.
Xenobiotica
; 47(12): 1027-1034, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27414183
8.
Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.
Xenobiotica
; 47(3): 255-266, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27225050
9.
Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK-357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation.
Biopharm Drug Dispos
; 38(6): 373-380, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28256717
10.
Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation.
Biopharm Drug Dispos
; 38(9): 543-552, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28948605
11.
The effects of the concentration-dependent erythrocyte distribution of TAK-802, a potent acetylcholinesterase inhibitor, on rat pharmacokinetics.
Biopharm Drug Dispos
; 37(8): 467-478, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27554287
12.
Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
Drug Metab Dispos
; 41(4): 727-34, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23298863
13.
Evaluation of low background liquid scintillation counter for non-clinical ADME studies.
Xenobiotica
; 43(6): 520-6, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23256624
14.
Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals.
Xenobiotica
; 43(2): 182-92, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22867273
15.
Species differences of organic anion transporters involved in the renal uptake of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, between rats and dogs.
Biopharm Drug Dispos
; 34(4): 236-46, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23529922
16.
Differences in the pharmacokinetics of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, in rats and dogs.
Drug Metab Dispos
; 40(4): 648-54, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22203697
17.
An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide.
Drug Metab Dispos
; 40(2): 249-58, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22028317
18.
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
Bioorg Med Chem
; 19(21): 6383-99, 2011 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21978946
19.
Chemical reactivity of ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242) in vitro.
Biopharm Drug Dispos
; 32(7): 408-25, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21887787
20.
In vitro micronucleus test in HepG2 transformants expressing a series of human cytochrome P450 isoforms with chemicals requiring metabolic activation.
Mutat Res
; 677(1-2): 1-7, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19501186